Japan Dry Eye Syndrome Market Size, Share, Trends and Forecast by Disease Type, Drug Type, Product, Distribution Channel, and Region, 2026-2034

The Japan dry eye syndrome market size was valued at USD 150.1 Million in 2025 and is projected to reach USD 202.1 Million by 2034, growing at a compound annual growth rate of 3.4% from 2026-2034.

The Japan dry eye syndrome market is witnessing significant growth with the increasing problem of dry eyes in the country due to the ever-increasing cases of ocular surface disorders. The Japanese population is aging at a rapid pace, and the use of digital gadgets is common among all ages. This is fueling the growth of the Japan dry eye syndrome market, with an increase in the need to find the best solutions to this problem. The developments in the study of the eyes and the changing face of the way the problem is being dealt with are all adding to the growth of the Japan dry eye syndrome market share.

KEY TAKEAWAYS AND INSIGHTS:

• By Disease Type: Evaporative dry eye syndrome dominated the market with a share of 60% in 2025 , driven by the high prevalence of meibomian gland dysfunction among Japan's aging population and prolonged digital screen exposure contributing to tear film instability.
• By Drug Type: Lubricant eye drops lead the market with a share of 49% in 2025 , owing to their widespread availability as over-the-counter solutions, ease of use, and established role as the first-line treatment for managing mild to moderate dry eye symptoms.
• By Product: Liquid drops hold the leading market share of 55% in 2025 , reflecting strong consumer preference for convenient, fast-acting formulations that provide immediate symptomatic relief and are compatible with varied lifestyles and treatment routines.
• By Distribution Channel: Retail pharmacies dominate the market with a share of 46% in 2025 , supported by the extensive network of community pharmacies across Japan offering accessible and trusted over-the-counter eye care products.
• Key Players: The Japan dry eye syndrome market features moderate competitive intensity, with established pharmaceutical companies and specialized ophthalmic firms competing through product innovation, formulation advancements, and strategic partnerships to expand their market presence.

The dry eye syndrome market in Japan is moving forward as healthcare providers, researchers, and patients understand the complex nature of the disease and strive to address the various aspects of the condition's management. In June 2023, Senju Pharmaceutical Co., Ltd. entered into a licensing agreement with biopharmaceutical firm Novaliq GmbH to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), a first-in-class, preservative-free treatment that directly targets tear evaporation for dry eye disease in Japan. The country is known to have a well-developed health infrastructure and uses advanced diagnostic tools to detect the disease. Its focus on preservative-free agents, innovative mucin secretagogues, and tear film stabilizers suggests that the country is familiar with methods for effective eye care. Digital technologies are also being integrated into traditional ophthalmological practice, thereby increasing access to individual patient management plans. Awareness campaigns about the importance of eye health have led more people to embrace the various dry eye treatments.

JAPAN DRY EYE SYNDROME MARKET TRENDS:

Rising Demand for Preservative-Free Ophthalmic Formulations

Japan is experiencing a notable shift toward preservative-free eye drops, driven by growing awareness of the adverse effects of preservatives on the ocular surface, including corneal epithelial damage and symptom aggravation during prolonged use. Both patients and clinicians are increasingly favoring gentler formulations for chronic dry eye management. The expanding availability of single-dose preservative-free artificial tears and therapeutic drops across pharmacies and hospitals reflects evolving clinical guidelines and patient preferences, reinforcing the demand for safer, well-tolerated ophthalmic solutions in the country.

Growing Adoption of Tear Film-Oriented Therapeutic Approaches

Japan is at the forefront of adopting tear film-oriented diagnosis and treatment strategies that address the root causes of dry eye rather than merely alleviating symptoms. This approach involves assessing tear film breakup patterns and tailoring therapies to restore tear stability, aqueous volume, and mucin secretion. Building on this paradigm, the concept of tear-film-oriented diagnosis (TFOD) and tear-film-oriented therapy (TFOT), first developed and widely applied in Japan, enables clinicians to classify dry eye subtypes based on tear film dynamics and breakup patterns, guiding more precise, component-targeted interventions. The integration of multi-disciplinary care combining ophthalmology, optometry, and lifestyle guidance is gaining traction, driving Japan dry eye syndrome market growth and encouraging the development of targeted interventions for different subtypes of the condition.

Increasing Focus on Digital Eye Strain-Related Dry Eye

The widespread use of digital devices across workplaces and daily life in Japan is contributing to a surge in screen-related dry eye symptoms, particularly among younger and working-age populations. Extended screen exposure reduces blink frequency and contributes to tear film instability, accelerating dry eye onset. For example, a large population-based study in Japan reported that individuals who used visual display terminals (VDTs) for >=5 hours per day had a significantly higher prevalence of dry eye, with up to around 36.5 % of women and 22.3 % of men affected, compared with those with minimal daily screen time, demonstrating the link between prolonged digital screen use and dry eye symptoms. Healthcare providers are increasingly incorporating digital eye strain assessments into routine eye care, while awareness campaigns are promoting preventive measures such as regular breaks, environmental adjustments, and appropriate lubricant use.

MARKET OUTLOOK 2026-2034:

Japan's dry eye syndrome market is poised for sustained growth, underpinned by the country's aging demographic profile, rising prevalence of screen-related ocular discomfort, and evolving clinical approaches to tear film management. Increasing awareness of eye health across all age groups, combined with expanding access to advanced diagnostic tools and therapeutic options, is strengthening the treatment landscape. Government-led healthcare initiatives promoting preventive eye care, alongside growing patient engagement with chronic disease management, are further reinforcing the long-term growth trajectory of the market. The market generated a revenue of USD 150.1 Million in 2025 and is projected to reach a revenue of USD 202.1 Million by 2034, growing at a compound annual growth rate of 3.4% from 2026-2034.

JAPAN DRY EYE SYNDROME MARKET REPORT SEGMENTATION:

Disease Type Insights:

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
• The evaporative dry eye syndrome dominates with a market share of 60% of the total Japan dry eye syndrome market in 2025.
• Evaporative dry eye syndrome, mainly associated with meibomian gland dysfunction, is the most common form of this condition in Japan. The leading share indicates the huge impact of environmental factors, screen time elongation, and age-related glandular changes on tear film stability. The aging demographic profile, together with the rapid spread of digital devices at workplaces and educational institutions, hastens the incidence of evaporative dry eye in Japan. The increasing acknowledgement of lipid layer inadequacy as a major cause in disrupting tear film is fueling demand for specific therapeutic interventions.
• Japanese healthcare providers are increasingly focused on targeted treatments that address the root causes of evaporative dry eye, such as warm compress therapies, lipid-based lubricants, and innovative ophthalmic solutions designed to restore tear film integrity. Clinical focus on the identification and management of meibomian gland dysfunction as a root cause is strengthening diagnostic accuracy and treatment effectiveness. Further reinforcement in the dominance of this segment across both hospital and community-based ophthalmology settings is the growing adoption of advanced imaging technologies for gland assessment.

Drug Type Insights:

• Anti-inflammatory Drugs
• Lubricant Eye Drops
• Autologous Serum Eye Drops
• The lubricant eye drops leads with a share of 49% of the total Japan dry eye syndrome market in 2025.
• Lubricating eye drops remain to be the core therapy for the treatment of dry eye conditions within Japan by providing symptomatic relief for patients belonging to all severity categories. The accessibility and easy availability of the eye drops within retail outlets and hospitals, along with their safety profile, appear to be making the therapy the preferred choice for mild and moderate cases of dry eye. Real-world usage data from a large crowdsourced study in Japan showed that among individuals with symptomatic dry eye, artificial tears were the most commonly used type of eye drop (used by 53.4 % of respondents), followed by hyaluronic acid solutions (33.1 %), highlighting the central role of lubricating drops in everyday management.
• The segment remains to benefit from an ongoing improvement in formulation technology to develop hyaluronic acid ingredients and lipid-enriched lubricants. Preservative-free single-dose forms are showing strong market appeal among patients with frequent-use requirements. They are intended to address the issue of long-term ocular surface safety. The over-the-counter format advantage, along with the growing awareness of the need to keep the eyes hydrated, is augmenting the strong market position of eye lubricating drops.

Product Insights:

• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
• The liquid drops dominates with a market share of 55% of the total Japan dry eye syndrome market in 2025.
• The most widely used dry eye treatment product types in Japan continue to be liquid drops due to the associated ease of administration and quick onset of relief. The dry eye treatment segment includes both prescription and non-prescription products, which range from simple artificial tears to complex therapeutic formulas targeting particular deficiencies in the tear film. The Japanese market favors liquid drop-type dry eye treatment products due to customer familiarity and practicality, as it suits all types of dry eye patients, from mild to severe, with either an active or less active lifestyle.
• The continued development of preservative-free single-dose liquid drop formats is further enhancing their position in the market, addressing consumer concerns related to long-term ocular surface safety. Innovative formulations featuring hyaluronic acids, lipid ingredients, and mucin-stimulating agents are increasing the scope of liquid drop therapy beyond primary hydration. The ease of portable formats, their increasing availability in stores, online pharmacies, as well as consumer awareness of correct usage, is keeping demand for liquid drop formats strong.

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• The retail pharmacies leads with a share of 46% of the total Japan dry eye syndrome market in 2025.
• The primary mode of product distribution for dry eye treatment is through retail pharmacies, which take advantage of the already extensive and well-established infrastructure in Japan. This channel is especially advantageous since it allows patients to access the wide product range available in over-the-counter lubricating eye drops and artificial tears from the numerous retail pharmacies available, which cover the entire country and give patients quick access to such dry eye treatment.
• The level of trust placed in pharmacists to give personalized recommendations on product selection and how to use it correctly contributes to a positive perception for the distribution method. The addition of health consultation services within retail pharmacies contributes to higher consumer engagement in the treatment guidelines set for the self-management of chronic eye conditions. The focus on eye health awareness promotions within retail pharmacies, strategic placement of products within the retail environment, as well as the increasing cooperation between pharmaceutical companies and retail pharmacies, all contribute to the continued market dominance of retail pharmacies.

Regional Insights:

• Kanto Region
• Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• The Kanto Region leads Japan's dry eye syndrome market, driven by its large urban population concentrated in Tokyo and surrounding metropolitan areas. Extensive healthcare infrastructure, high concentration of ophthalmology specialists, and significant prevalence of screen-related ocular strain among office workers are sustaining strong demand for both prescription and over-the-counter dry eye treatments across the region.
• The Kinki Region represents a significant market share, supported by well-established ophthalmology networks and major medical research institutions in Osaka and Kyoto. Growing awareness of dry eye management, expanding availability of advanced therapeutic options, and rising patient engagement with preventive eye care services are strengthening treatment adoption across urban and suburban communities in the region.
• The Central/Chubu Region is experiencing steady growth in dry eye treatment adoption, fueled by expanding healthcare access and rising digital device usage among the working population. Increasing emphasis on preventive eye care services, growing distribution of ophthalmic products through retail pharmacies, and enhanced diagnostic capabilities at regional hospitals are supporting sustained market development.
• The Kyushu-Okinawa Region is contributing to market expansion through improved regional healthcare delivery and growing public awareness of ocular health. Increasing availability of specialized ophthalmic products in retail and hospital pharmacy settings, along with expanding access to ophthalmology consultations in semi-urban areas, is driving broader adoption of dry eye treatments across the region.
• The Tohoku Region is witnessing gradual growth in the dry eye syndrome treatment market, supported by government initiatives to enhance healthcare accessibility in rural and semi-rural areas. Increasing adoption of modern diagnostic tools at regional eye care facilities and expanding community pharmacy networks are improving patient access to effective dry eye management solutions.
• The Chugoku Region is expanding its dry eye care capabilities through improved distribution of ophthalmic products and growing integration of telemedicine in eye health services. Rising patient engagement with preventive ocular health practices and enhanced awareness campaigns in community settings are encouraging broader treatment adoption across the region's urban and rural populations.
• The Hokkaido Region is advancing dry eye treatment awareness through seasonal health campaigns addressing cold and dry climate-related ocular discomfort. Strengthening pharmacy networks, increasing specialist consultations, and growing adoption of lubricant-based therapies during harsh winter months are supporting steady market growth and improving patient outcomes across the territory.
• The Shikoku Region is demonstrating growth potential through enhanced regional healthcare programs and increasing availability of dry eye treatments in community pharmacies. Rising awareness of chronic eye health management, expanding telemedicine services for remote consultations, and growing emphasis on age-related ocular care are collectively supporting gradual market development across the region.

MARKET DYNAMICS:

Growth Drivers:

• Why is the Japan Dry Eye Syndrome Market Growing ?
• Rapidly Aging Population Driving Higher Disease Prevalence
• Japan's demographic landscape, characterized by one of the world's highest proportions of elderly citizens, is a fundamental growth driver for the dry eye syndrome market. Age-related changes in tear gland function, hormonal shifts, and increased prevalence of systemic conditions such as diabetes and autoimmune disorders directly contribute to higher rates of dry eye among older adults. In fact, clinical research in Japan has shown that among individuals aged over 60, definite dry eye was observed in approximately 73.5 % of eyes examined, highlighting the significantly elevated burden of dry eye in an elderly Japanese population. As the elderly population continues to expand, healthcare systems are adapting by integrating routine eye health screenings into geriatric care programs. Ophthalmologists and primary care providers are increasingly emphasizing early detection and proactive management of dry eye as part of comprehensive elder care. This demographic-driven demand is expected to remain a consistent growth catalyst throughout the forecast period.
• Escalating Digital Device Usage Across All Demographics
• The pervasive use of smartphones, computers, tablets, and other digital devices in Japan's highly connected society is significantly contributing to the rising incidence of dry eye symptoms. Prolonged screen exposure reduces blink frequency, disrupts tear film stability, and accelerates evaporative tear loss, leading to increased discomfort and demand for effective treatments. A cross-sectional study of Japanese office workers found that those using visual display terminals (VDTs) for more than 8 hours per day had a significantly higher risk of dry eye disease and exhibited short tear break-up time (<= 5 seconds), a clinical indicator of tear instability, with 78.6 % of participants showing this sign, highlighting the strong association between extended screen use and ocular surface dysfunction in digital work environments. This trend affects not only working-age adults in office environments but also younger populations engaged in extensive digital learning and entertainment activities.
• Advancements in Ophthalmic Treatment Approaches and Formulations
• Continuous innovation in ophthalmic drug development and treatment methodologies is strengthening the therapeutic landscape for dry eye syndrome in Japan. The evolution from basic artificial tear formulations to advanced mucin secretagogues, diquafosol-based therapies, and lipid-stabilizing solutions represents a significant advancement in addressing the multifactorial nature of the condition. Topical rebamipide ophthalmic suspension (Mucosta(R)) is a clinically validated mucin secretagogue that significantly improves tear stability, corneal staining, tear break-up time, and symptoms, highlighting Japan's role in mechanism-targeted therapies. These newer therapeutic approaches target specific pathophysiological mechanisms, offering more effective and tailored relief compared to conventional treatments. The development of novel drug delivery systems, including preservative-free single-dose formats and sustained-release formulations, is improving patient compliance and treatment outcomes.

Market Restraints:

• What Challenges the Japan Dry Eye Syndrome Market is Facing?
• Underdiagnosis and Low Treatment-Seeking Behavior
• Despite the high prevalence of dry eye in Japan, a significant proportion of affected individuals remain undiagnosed or do not actively seek medical treatment. Many patients perceive dry eye symptoms as minor discomforts rather than a medical condition requiring professional intervention. This underdiagnosis limits market penetration and prevents patients from accessing appropriate therapeutic solutions. Cultural tendencies toward self-management and reluctance to visit specialists for perceived minor ailments further contribute to delayed diagnosis and treatment initiation.
• Reimbursement Pressures and Healthcare Cost Containment
• Japan's ongoing healthcare cost containment measures and periodic drug price revisions create pricing pressures for ophthalmic pharmaceutical manufacturers. Regular downward adjustments to National Health Insurance drug prices can reduce revenue potential for prescription dry eye treatments and may discourage investment in newer therapies. These reimbursement constraints can limit the commercial viability of innovative formulations and affect the pace at which advanced therapeutic options become widely available to patients.
• Limited Awareness of Chronic Disease Management Needs
• While awareness of dry eye syndrome is growing, many patients still lack understanding of the chronic and progressive nature of the condition. Inconsistent treatment adherence and premature discontinuation of therapy remain common challenges, particularly among patients who experience temporary symptom relief and assume the condition is resolved. The gap between symptom awareness and understanding of the need for sustained management undermines treatment persistence and reduces the long-term therapeutic impact of available products.

COMPETITIVE LANDSCAPE:

• The Japan dry eye syndrome market is characterized by a moderately competitive environment in which established pharmaceutical companies and specialized ophthalmic firms are actively expanding their product portfolios. Competition is driven by innovation in drug formulations, the development of preservative-free and targeted therapeutic solutions, and the pursuit of regulatory approvals for novel treatment approaches. Companies are investing in clinical research to differentiate their offerings through improved efficacy profiles, enhanced patient convenience, and advanced delivery mechanisms. Strategic collaborations, licensing agreements, and partnerships with international ophthalmic innovators are further intensifying competitive dynamics. The market is also influenced by the growing presence of over-the-counter eye care products, which broadens the competitive landscape beyond prescription pharmaceuticals. As the treatment paradigm evolves, market players are refining their strategies to address unmet clinical needs, strengthen brand recognition among healthcare professionals, and capture greater market share across both hospital and retail pharmacy channels.
• KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the Japan dry eye syndrome market?

2. What is the projected growth rate of the Japan dry eye syndrome market?

3. Which disease type held the largest Japan dry eye syndrome market share?

4. What are the key factors driving market growth?

5. What are the major challenges facing the Japan dry eye syndrome market?